Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes

Medicine & Life Sciences

• Accidental Falls 11%
• Apolipoprotein A-I 77%
• Atorvastatin 81%
• Coronary Disease 6%
• Cytochrome P-450 CYP3A 8%
• Fibric Acids 30%
• Fluvastatin 10%
• HDL Cholesterol 60%
• Hydroxymethylglutaryl-CoA Reductase Inhibitors 43%
• LDL Cholesterol 13%
• Pharmacokinetics 5%
• Pravastatin 39%
• Primary Prevention 7%
• Rosuvastatin Calcium 40%
• Secondary Prevention 7%
• Simvastatin 80%
• Therapeutics 3%
• Thiazolidinediones 9%
• Type 2 Diabetes Mellitus 50%

Chemistry

• Antitriglyceride 59%
• Atorvastatin 100%
• Cytochrome P450 12%
• Fluvastatin 18%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 97%
• Lipophilicity 11%
• Pharmacokinetics 8%
• Pravastatin 73%
• Reduction 5%
• Rosuvastatin 72%
• Simvastatin 99%